Clindamycin Phosphate And Benzoyl Peroxide Gel
NDC Package 70771-1450-4

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Clindamycin Phosphate And Benzoyl Peroxide gel is 1.2%/5% is indicated for the topical treatment of inflammatory acne vulgaris in patients 12 years and older. This formulation utilizes a gel delivery system. Marketed by Zydus Lifesciences Limited, this product is identified by NDC 70771-1450 and is authorized under FDA application ANDA210794.

Identification & Billing

NDC Package Code
70771-1450-4
Package Description
1 TUBE in 1 CARTON / 45 g in 1 TUBE
Product Code
70771-1450
11-Digit Billing Format
70771145004
RxNorm Crosswalk
  • RxCUI: 358917 - clindamycin phosphate 1 % / benzoyl peroxide 5 % Topical Gel
  • RxCUI: 358917 - benzoyl peroxide 0.05 MG/MG / clindamycin 0.01 MG/MG Topical Gel
  • RxCUI: 358917 - benzoyl peroxide 5 % / clindamycin 1 % (as clindamycin phosphate 1.2 % ) Topical Gel
  • RxCUI: 358917 - benzoyl peroxide 5 % / clindamycin 1 % Topical Gel

Clinical Specifications

Proprietary Name
Clindamycin Phosphate And Benzoyl Peroxide
Non-Proprietary Name
Clindamycin Phosphate And Benzoyl Peroxide
Substance Name
Benzoyl Peroxide; Clindamycin Phosphate
Dosage Form
Gel - A semisolid3 dosage form that contains a gelling agent to provide stiffness to a solution or a colloidal dispersion.4 A gel may contain suspended particles.
Administration Route
Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
Active Ingredient(s)
Pharmacologic Class
Usage Information
Clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% is indicated for the topical treatment of inflammatory acne vulgaris in patients 12 years and older.

Regulatory & Marketing

Labeler Name
Zydus Lifesciences Limited
Product Type
Human Prescription Drug
FDA Application #
ANDA210794
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-07-2019
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70771-1450-4 identifies a specific commercial package of 1 tube in 1 carton / 45 g in 1 tube of Clindamycin Phosphate And Benzoyl Peroxide, a human prescription drug labeled by Zydus Lifesciences Limited. This gel is formulated for topical use and contains benzoyl peroxide; clindamycin phosphate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Zydus Lifesciences Limited on March 07, 2019. The current certification is valid through December 31, 2026.

How is this Zydus Lifesciences Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70771145004. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70771-1450-4
11-Digit CMS (5-4-2)
70771-1450-04

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.